Literature DB >> 16031293

A comparison of serotyping, BRENDA-typing and incompatibility grouping, and toxin testing of haemolytic Escherichia coli isolated from piglets before and after weaning.

D J Hampson1, K A Bettelheim, P J Winter, R B Marshall, M W Wilson.   

Abstract

Before weaning, some young pigs in a research piggery excreted in their faeces a weakly haemolytic non-enterotoxigenic serotype of Escherichia Coli. After weaning, all of the pigs excreted strongly haemolytic Escherichia coli of known enteropathogenic serotypes (0-138 and 0-139). The 0-138 serotype produced vero cell toxin, whilst the 0-139 serotype elaborated heat labile enterotoxin. Haemolytic enterotoxigenic E. Coli were also recovered from three-week-old unweaned piglets with so-called ;milk scours; and from pigs with post-weaning diarrhoea on two local commercial piggeries. Selected haemolytic isolates were compared using serotyping, bacterial restriction endonuclease DNA analysis (BRENDA) and incompatibility grouping. The three typing methods divided most of the isolates into the same groupings; the exceptions were two isolates with the same BRENDA pattern and incompatibility group, but with different H-serotypes, and eleven isolates with the same serotype and BRENDA pattern but which showed differences in colony compatibility such that they were divided into five subgroups of a single incompatibility type.

Entities:  

Year:  1986        PMID: 16031293     DOI: 10.1080/00480169.1986.35310

Source DB:  PubMed          Journal:  N Z Vet J        ISSN: 0048-0169            Impact factor:   1.628


  2 in total

1.  Investigation of the source of haemolytic Escherichia coli infecting weaned pigs.

Authors:  D J Hampson; Z F Fu; I D Robertson
Journal:  Epidemiol Infect       Date:  1987-08       Impact factor: 2.451

2.  Managemental influences on the selective proliferation of two strains of haemolytic Escherichia coli in weaned pigs.

Authors:  D J Hampson; Z F Fu; K A Bettleheim; M W Wilson
Journal:  Epidemiol Infect       Date:  1988-04       Impact factor: 2.451

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.